Top Research Papers from The Ottawa Hospital 2016-2018

June 7, 2019

Did you know that researchers at The Ottawa Hospital publish an average of four new scientific papers every single day? Our research is advancing science and improving health on a massive scale – both at home and around the world.

The list below represents the “top research papers” from The Ottawa Hospital, as measured by citations (for 2016-2018) and Journal Impact Factor (for 2018) using several different categories. Our researchers are also leaders in conducting high quality, reproducible research, although this is more difficult to measure.

The papers below are referenced in the language in which they were written, however lay summaries are available in English and French.

Read more about how the list was developed and how our research impact has grown over time.

Researchers at The Ottawa Hospital are also affiliated with the University of Ottawa.

Top Papers by Citations


  • UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia (Aissa Benyoucef, Marjorie Brand, Genes and Development 2016, 39 citations, paper, lay summary)
  • Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension (Baohua Jiang, Duncan Stewart, American Journal of Respiratory Cell and Molecular Biology, 2016, 32 citations, paper)
  • Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy (Marie-Claude Bourgeois-Daigneault,  John Bell, Science Translational Medicine, 2018, 28 citations, paper, lay summary)
  • UTX demethylase activity is required for satellite cell-mediated muscle regeneration (Hervé Faralli, Jeffrey Dilworth, Journal of Clinical Investigation, 2016, 20 citations, paper, lay summary)
  • Notch Signaling Rescues Loss of Satellite Cells Lacking Pax7 and Promotes Brown Adipogenic Differentiation (Alessandra Pasut, Michael Rudnicki, Cell Reports, 2016, 19 citations, paper)

Clinical Research

  • Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study (Glenwood Goss, The Lancet Oncology, 2016, 152 citations, paper, lay summary)
  • Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial (Harold Atkins,  Mark Freedman, The Lancet, 2016, 75 citations, paper, lay summary)
  • Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma (Shawn Aaron, JAMA, 2017, 74 citations, paper, lay summary)
  • Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference (Christopher McCudden, Clinical Chemistry and Laboratory Medicine, 2016, 43 citations, paper)
  • Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer (Glenwood Goss, Journal of Thoracic Oncology, 2017, 42 citations, paper)

Research Reviews, Methods and Policy Papers

  • Decision aids for people facing health treatment or screening decisions (Dawn Stacey, Cochrane databases of Systematic Reviews, 2017, 123 citations, paper, lay summary)
  • Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study (David Moher, PLOS Medicine, 2016, 105 citations, paper, lay summary)
  • Increasing value and reducing waste in biomedical research: who's listening? (David Moher, The Lancet, 2016, 98 citations, paper)
  • AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both (Beverley Shea, British Medical Journal 2017, 87 citations, paper)
  • Applications of 3D printing in cardiovascular diseases (Frank Rybicki, Nature Reviews, 2016, 57 citations, paper)

Co-authored Papers

  • Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report (Philip Wells, Chest, 2016, 1,103 citations, paper)
  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial (Christina Canil, The Lancet, 2016, 1,007 citations, paper)
  • Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 (Lauralyn McIntyre, Intensive Care Medicine, 2017, 675 citations, paper)
  • ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions (Mohammed Ansari, Beverley Shea, Peter Tugwell, Lucy Turner, British Medical Journal, 2016, 352 citations, paper)
  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial (Scott Laurie, The Lancet Oncology, 2016, 267 cites, paper)

Top Papers by Journal Impact Factor (2018)


  • Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy (Harinad Maganti, Hani Jrade, Caryn Ito, William Stanford, Cancer Discovery, JIF 24.4, paper, lay summary)
  • The Dystrophin Glycoprotein Complex Regulates the Epigenetic Activation of Muscle Stem Cell Commitment (Natasha Chang, Michael Rudnicki, Cell Stem Cell, JIF 23.3, paper, lay summary)
  • Dimethyl fumarate potentiates oncolytic virotherapy through NF-kappa B inhibition (Mohammed Selman, Jean-Simon Diallo, Science Translational Medicine, JIF 16.7, paper, lay summary)
  • Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy (Marie-Claude Bourgeois-Daigneault,  John Bell, Science Translational Medicine, JIF 16.7, paper, lay summary)
  • Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade (Jonathan Hodgins, Michele Ardolino, Journal of Clinical Investigation, JIF 13.25, paper, lay summary)

Clinical Research

  • Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery (Dean Fergusson, New England Journal of Medicine, JIF 79.3, paper, lay summary)
  • Apixaban to Prevent Venous Thromboembolism in Patients with Cancer (Marc Carrier, Philip Wells, New England Journal of Medicine, JIF 79.3, paper, lay summary)
  • Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial (Shi Wu Wen, Mark Walker, British Medical Journal, JIF 23.6, paper, lay summary)
  • Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial (Glenwood Gloss, JAMA Oncology JIF 20.9, paper)
  • Diagnosis of Pulmonary Embolism During Pregnancy A Multicenter Prospective Management Outcome Study (Gregoire Le Gal, Annals of Internal Medicine, JIF 19.4, paper)

Research Reviews, Methods and Policy Papers

  • Acute Infection and Myocardial Infarction (Vicente Corrales-Medina, New England Journal of Medicine, JIF 79.3, paper)
  • Canada's global health role: supporting equity and global citizenship as a middle power (Peter Tugwell, The Lancet JIF 53.3, paper, lay summary)
  • Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies The PRISMA-DTA Statement (Matthew McInnes, JAMA, JIF 47.7, paper, lay summary)
  • Stem Cell Transplantation to Treat Multiple Sclerosis (Harold Atkins, JAMA, JIF 47.7, paper)
  • Venous Thromboembolism Advances in Diagnosis and Treatment (Philip Wells, JAMA, JIF 47.7, paper)
  • Health Data and Privacy in the Digital Era (Kumanan Wilson, JAMA JIF 47.7, paper)

Co-authored Papers

  • FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer (Christine Cripps, New England Journal of Medicine, JIF 79.3, paper)
  • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia (David MacDonald, New England Journal of Medicine, JIF 79.3, paper, lay summary)
  • Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma (Christopher Bredeson, New England Journal of Medicine, JIF 79.3, paper)
  • Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty (Paul Kim, Wade Gofton, Philip Wells, Marc Rodger, Marc Carrier, Doug Coyle, New England Journal of Medicine, JIF 79.3, lay summary, paper)
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study (Paul Whitley-Price, The Lancet Oncology, JIF 36.4, paper)

Support research at The Ottawa Hospital.

Related Stories

The Ottawa Hospital’s research impact continues to grow

 Top Research Papers from The Ottawa Hospital 2015-2017.

The Ottawa Hospital: Inspired by research. Driven by compassion 
The Ottawa Hospital is one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and an annual budget of over $1.2 billion. Our focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, we deliver specialized care to the Eastern Ontario region, but our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care. See for more information about research at The Ottawa Hospital.

University of Ottawa: —A crossroads of cultures and ideas
The University of Ottawa is home to over 50,000 students, faculty and staff, who live, work and study in both French and English. Our campus is a crossroads of cultures and ideas, where bold minds come together to inspire game-changing ideas. We are one of Canada’s top 10 research universities—our professors and researchers explore new approaches to today’s challenges. One of a handful of Canadian universities ranked among the top 200 in the world, we attract exceptional thinkers and welcome diverse perspectives from across the globe.

Media Contact
Jennifer Ganton
Director, Communications and Public Relations
Ottawa Hospital Research Institute
Office: 613-798-5555 x 73325
Cell: 613-614-5253